On Monday, Moderna Inc said that initial data from tests of its COVID-19 vaccine candidate showed that it produced protective antibodies in a small group of healthy volunteers.
The data was gathered from eight people who were a part of a 45-subject safety trial that started in March. The Moderna vaccine is one among the many-- more than a 100 potential vaccines to protect against the deadly COVID-19. Ever since the coronavirus outbreak was declared a pandemic by the WHO, drugmakers have been racing to find a cure.
“These are significant findings but it is a Phase 1 clinical trial that only included eight people. It was designed for safety. Not for efficacy,” said Dr. Amesh Adalja, in infectious disease expert at the Johns Hopkins Center for Health Security who was not a part of the study said.
The initial data from the tests offer hope to this world that has come to a standstill because of the highly infectious virus.
The virus, which emerged in the Chinese city of Wuhan last December, has put strains on the global economy with many countries announcing full or partial lockdowns in order to contain its spread. Since its conception, the virus spread like wildfire across the globe, infecting more than 4.9 million people and killing over 3,20,000.
Many countries that have experienced the slowing down of the spread are concerned about a second wave that would have devastating implications on both human life and the economy.